Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 5,370 Shares

Natera, Inc. (NASDAQ:NTRAGet Rating) CEO Steven Leonard Chapman sold 5,370 shares of the business’s stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $41.56, for a total transaction of $223,177.20. Following the transaction, the chief executive officer now directly owns 103,779 shares of the company’s stock, valued at $4,313,055.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

  • On Tuesday, January 3rd, Steven Leonard Chapman sold 8,212 shares of Natera stock. The shares were sold at an average price of $39.55, for a total transaction of $324,784.60.
  • On Wednesday, December 28th, Steven Leonard Chapman sold 2,605 shares of Natera stock. The shares were sold at an average price of $39.84, for a total transaction of $103,783.20.
  • On Friday, December 23rd, Steven Leonard Chapman sold 1,660 shares of Natera stock. The shares were sold at an average price of $42.30, for a total transaction of $70,218.00.
  • On Wednesday, December 7th, Steven Leonard Chapman sold 2,645 shares of Natera stock. The shares were sold at an average price of $38.31, for a total transaction of $101,329.95.

Natera Price Performance

NTRA stock opened at $42.94 on Wednesday. Natera, Inc. has a one year low of $26.10 and a one year high of $74.82. The company’s fifty day moving average price is $39.55 and its 200-day moving average price is $44.06. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.95 and a current ratio of 3.10. The company has a market capitalization of $4.19 billion, a PE ratio of -7.56 and a beta of 1.28.

Natera (NASDAQ:NTRAGet Rating) last released its earnings results on Tuesday, November 8th. The medical research company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.17. Natera had a negative net margin of 70.34% and a negative return on equity of 109.07%. The firm had revenue of $210.64 million for the quarter, compared to the consensus estimate of $208.31 million. On average, equities analysts anticipate that Natera, Inc. will post -5.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Raymond James upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $58.00 target price for the company in a research report on Wednesday, January 18th. Credit Suisse Group cut their target price on shares of Natera from $70.00 to $55.00 and set an “outperform” rating for the company in a research report on Monday, November 14th. StockNews.com started coverage on shares of Natera in a research report on Wednesday, October 12th. They issued a “sell” rating for the company. Piper Sandler reiterated an “overweight” rating and issued a $70.00 price target on shares of Natera in a research report on Tuesday, January 17th. Finally, Robert W. Baird dropped their price target on shares of Natera from $72.00 to $65.00 in a research report on Wednesday, November 9th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $80.00.

Hedge Funds Weigh In On Natera

Several hedge funds have recently modified their holdings of NTRA. Bank of New York Mellon Corp lifted its holdings in shares of Natera by 6.7% in the first quarter. Bank of New York Mellon Corp now owns 820,974 shares of the medical research company’s stock worth $33,399,000 after buying an additional 51,791 shares in the last quarter. US Bancorp DE raised its stake in Natera by 20.0% during the first quarter. US Bancorp DE now owns 16,180 shares of the medical research company’s stock valued at $658,000 after purchasing an additional 2,698 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Natera by 215.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company’s stock valued at $83,000 after purchasing an additional 1,399 shares in the last quarter. Bank of Montreal Can raised its stake in Natera by 80.6% during the first quarter. Bank of Montreal Can now owns 130,062 shares of the medical research company’s stock valued at $5,390,000 after purchasing an additional 58,049 shares in the last quarter. Finally, MetLife Investment Management LLC purchased a new stake in Natera during the first quarter valued at $209,000. Hedge funds and other institutional investors own 93.81% of the company’s stock.

About Natera

(Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Articles

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.